Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Decrease in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 268,742 shares, a decline of 85.3% from the August 31st total of 1,828,008 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 1,305,660 shares, the short-interest ratio is presently 0.2 days.

Xtant Medical Stock Performance

Shares of XTNT stock traded down $0.00 during trading on Friday, reaching $0.38. The company had a trading volume of 166,139 shares, compared to its average volume of 4,752,440. The firm’s 50 day simple moving average is $0.37 and its two-hundred day simple moving average is $0.45. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.16 and a quick ratio of 1.05. Xtant Medical has a one year low of $0.27 and a one year high of $0.95. The company has a market capitalization of $52.71 million, a PE ratio of -4.70 and a beta of -0.15.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.The company had revenue of $23.03 million for the quarter, compared to the consensus estimate of $24.88 million.

Wall Street Analysts Forecast Growth

Separately, Loop Capital set a $1.00 price target on shares of Xtant Medical in a report on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $1.00.

Institutional Trading of Xtant Medical

Several large investors have recently modified their holdings of the company. Tradition Wealth Management LLC acquired a new position in Xtant Medical in the 4th quarter valued at $79,000. Hillsdale Investment Management Inc. acquired a new position in Xtant Medical during the 4th quarter worth $284,000. Renaissance Technologies LLC lifted its position in Xtant Medical by 7.3% during the 1st quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock worth $551,000 after acquiring an additional 67,550 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Xtant Medical during the 2nd quarter worth $2,516,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and marketing surgical products for spinal and orthopedic procedures. The company’s portfolio includes biologic products designed to support bone growth and tissue repair, as well as spinal implants and related surgical instruments.

Its products are used by surgeons and hospitals in procedures involving spinal fusion, reconstruction and other orthopedic applications. Xtant’s biologics portfolio includes allograft and other regenerative solutions, while its hardware offerings include implants and instrumentation intended to support spinal stabilization and correction.

Xtant Medical is headquartered in Belgrade, Montana, and primarily serves the U.S.